All In Biotech

Drug Trial Radar · NCT00403494

A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease

A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease

Last checked: Nov 20, 2026Latest source record: Jan 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

190

Actual

Start

Dec 2006

Primary completion

Nov 2008

Study completion Jan 2009

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Nov 23, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether sapropterin dihydrochloride is safe and effective in the treatment of intermittent claudication (IC) caused by peripheral arterial disease (PAD).

Conditions

  • Intermittent Claudication

Interventions

  • PlaceboOther

    Subjects receive matching oral Placebo twice daily for 24 weeks.

  • Sapropterin DihydrochlorideDrug

    Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Peak Walking Time (PWT) From BaselineTime frame: Baseline and up to Week 24
  2. Number of Subjects With Adverse Events (AEs)Time frame: Up to 24-weeks

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Ana, California

  • Site not named

    Santa Rosa, California

  • Site not named

    Clearwater, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Conyers, Georgia

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Auburn, Maine

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Portland, Oregon

  • Site not named

    Knoxville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Norfolk, Virginia

  • Site not named

    Richmond, Virginia

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Corrientes, Argentina

  • Site not named

    Santa Fe, Argentina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.